We would infer from this data that a significant percentage of these patients were likely offered endocrine therapy as adjuvant treatment for their breast cancer, but we are unable to determine whether tamoxifen was utilized, versus an aromatase inhibitor, or whether there was a causal relationship with the patients’ subsequent endometrial cancer. The gene discussed is CYP19A1; the disease is breast carcinoma.